Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ClAraC versus FLAMSA before allogeneic stem cell transplantation in high‑risk AML or advanced MDS
2010-021944-17Phase 2Completed
- Sponsor
- Hannover Medical School
- Start
- Mar 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of clofarabine, cytarabine, fludarabine and amsacrine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Hannover Medical School. Primary endpoint: Event-free survival. Started Mar 2011; status: completed.
02
Drugs
clofarabinecytarabinefludarabineamsacrine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2010-021944-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021944-17.